US2003086947A1PendingUtilityA1

Vaccine against papillomatous digital dermatitis (PDD)

39
Assignee: TOWNSEND & TOWNSEND & CREW LLPPriority: Oct 3, 1997Filed: Mar 1, 2000Published: May 8, 2003
Est. expiryOct 3, 2017(expired)· nominal 20-yr term from priority
Inventors:Richard L. WalkerDeryck H. ReadDavid W. HirdRance B. LefebvreSteven L. BerryJames S. CullorHank M. Lefler
A61P 31/00A61P 31/04A61P 17/00C07K 14/20A61K 2039/521A61K 38/00Y10S424/823C12R 2001/01C12N 1/205A61K 39/0225
39
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

This invention relates to the diagnosis and prevention of ungulate diseases caused by the spirochete bacteria Treponema. The invention specifically relates to isolated cultures of this spirochete and isolated nucleic acids and proteins.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A biologically pure culture of ungulate Treponema.  
     
     
         2 . The culture of  claim 1 , having all the characteristics of Treponema strain 1-9185MED (ATCC Accession No. 202030), Treponema strain 2-1498 (ATCC Accession No. 202031), Treponema strain 7-2009 (ATCC Accession No. ______), Treponema strain 9-3301 (ATCC Accession No. ______), Treponema strain 9-3143 (ATCC Accession No. ______), Treponema strain 9-3528 (ATCC Accession No. ______), Treponema strain 9-3379 (ATCC Accession No. ______), or Treponema strain 9-227 (ATCC Accession No. ______).  
     
     
         3 . The culture of  claim 2 , which is selected from the group consisting of Treponema strain 1-9185MED (ATCC Accession No. 202030), Treponema strain 2-1498 (ATCC Accession No. 202031), Treponema strain 7-2009 (ATCC Accession No. ______), Treponema strain 9-3301 (ATCC Accession No. ______), Treponema strain 9-3143 (ATCC Accession No. ______), Treponema strain 9-3528 (ATCC Accession No. ______), Treponema strain 9-3379 (ATCC Accession No. ______), and Treponema strain 9-227 (ATCC Accession No. ______).  
     
     
         4 . A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an immunogenically effective amount of an ungulate Treponema antigen.  
     
     
         5 . The composition of  claim 4 , further comprising an antigen from an organism that causes ungulate foot rot selected from the group consisting of  Fusobacterium necrophorum, Porphyromonas levii,  and  Dichelobacter nodosus.    
     
     
         6 . The composition of  claim 4 , wherein the ungulate Treponema antigen is from Treponema strain 1-9185MED (ATCC Accession No. 202030), Treponema strain 2-1498 (ATCC Accession No. 202031), Treponema strain 7-2009 (ATCC Accession No. ______), Treponema strain 9-3301 (ATCC Accession No. ______), Treponema strain 9-3143 (ATCC Accession No. ______), Treponema strain 9-3528 (ATCC Accession No. ______), Treponema strain 9-3379 (ATCC Accession No. ______), or Treponema strain 9-227 (ATCC Accession No. ______).  
     
     
         7 . The composition of  claim 4 , wherein the antigen is a biologically pure culture of Treponema.  
     
     
         8 . The composition of  claim 7 , wherein the culture is selected from the group consisting of Treponema strain 1-9185MED (ATCC Accession No. 202030), Treponema strain 2-1498 (ATCC Accession No. 202031), Treponema strain 7-2009 (ATCC Accession No. ______), Treponema strain 9-3301 (ATCC Accession No. ______), Treponema strain 9-3143 (ATCC Accession No. ______), Treponema strain 9-3528 (ATCC Accession No. ______), Treponema strain 9-3379 (ATCC Accession No. ______), and Treponema strain 9-227 (ATCC Accession No. ______).  
     
     
         9 . The composition of  claim 4 , wherein the ungulate Treponema antigen is an isolated Treponema polypeptide.  
     
     
         10 . The composition of  claim 9 , wherein the polypeptide is recombinantly produced.  
     
     
         11 . A method for inducing an immune response against ungulate Treponema, the method comprising the administration to an ungulate animal of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an immunogenically effective amount of an ungulate Treponema antigen.  
     
     
         12 . The method of  claim 11 , wherein the Treponema antigen is from Treponema strain 1-9185MED (ATCC Accession No. 202030), Treponema strain 2-1498 (ATCC Accession No. 202031), Treponema strain 7-2009 (ATCC Accession No. ______), Treponema strain 9-3301 (ATCC Accession No. ______), Treponema strain 9-3143 (ATCC Accession No. ______), Treponema strain 9-3528 (ATCC Accession No. ______), Treponema strain 9-3379 (ATCC Accession No. ______), or Treponema strain 9-227 (ATCC Accession No. ______).  
     
     
         13 . The method of  claim 11 , wherein the antigen is a biologically pure culture of Treponema.  
     
     
         14 . The method of  claim 13 , wherein the culture is selected from the group consisting of Treponema strain 1-9185MED (ATCC Accession No. 202030), Treponema strain 2-1498 (ATCC Accession No. 202031), Treponema strain 7-2009 (ATCC Accession No. ______), Treponema strain 9-3301 (ATCC Accession No. ______), Treponema strain 9-3143 (ATCC Accession No. ______), Treponema strain 9-3528 (ATCC Accession No. ______), Treponema strain 9-3379 (ATCC Accession No. ______), and Treponema strain 9-227 (ATCC Accession No. ______).  
     
     
         15 . The method of  claim 11 , wherein the pharmaceutical composition is administered parenterally.  
     
     
         16 . The method of  claim 11 , wherein the pharmaceutical composition further comprises a bovine respiratory syncytial virus antigen, a bovine Herpes virus antigen, a leptospiral antigen, a bovine diarhhea virus antigen, a bovine parainfluenza virus antigen, a vesicular stomatitis virus antigen, a malignant catarrhal fever virus antigen, a blue tongue virus antigen, a pseudorabies virus antigen, a rabies virus antigen, a rinderpest virus antigen, a  Fusobacterium necrophorum  antigen, a  Dichelobacter nodosus  antigen, or a Clostridia spp. antigen.  
     
     
         17 . The method of  claim 11 , wherein the pharmaceutical composition further comprises an antigen from an organism that causes ungulate foot rot selected from the group consisting of  Fusobacterium necrophorum, Porphyromonas levii,  and  Dichelobacter nodosus.    
     
     
         18 . A method of detecting the presence of antibodies specifically immunoreactive with an ungulate Treponema antigen in a biological sample, the method comprising: 
 contacting the sample with the Treponema antigen, thereby forming a antigen/antibody complex; and    detecting the presence or absence of the complex.    
     
     
         19 . The method of  claim 18 , wherein the Treponema antigen is from Treponema strain 1-9185MED (ATCC Accession No. 202030), Treponema strain 2-1498 (ATCC Accession No. 202031), Treponema strain 7-2009 (ATCC Accession No. ______), Treponema strain 9-3301 (ATCC Accession No. ______), Treponema strain 9-3143 (ATCC Accession No. ______), Treponema strain 9-3528 (ATCC Accession No. ______), Treponema strain 9-3379 (ATCC Accession No. ______), or Treponema strain 9-227 (ATCC Accession No. ______).  
     
     
         20 . The method of  claim 18 , wherein the biological sample is bovine serum.  
     
     
         21 . The method of  claim 18 , wherein the antigen is an isolated Treponema polypeptide.  
     
     
         22 . The method of  claim 18 , wherein the antigen is immobilized on a solid surface.  
     
     
         23 . The method of  claim 18 , wherein the complex is detected using a labeled anti-bovine antibody.  
     
     
         24 . A method of detecting the presence of ungulate Treponema in a biological sample, the method comprising: 
 contacting the sample with an antibody specifically immunoreactive with a Treponema antigen, thereby forming a antigen/antibody complex; and    detecting the presence or absence of the complex.    
     
     
         25 . The method of  claim 23 , wherein the antibody is specifically immunoreactive with an antigen from a strain selected from the group consisting of Treponema strain 1-9185MED (ATCC Accession No. 202030), Treponema strain 2-1498 (ATCC Accession No. 202031), Treponema strain 7-2009 (ATCC Accession No. ______), Treponema strain 9-3301 (ATCC Accession No. ______), Treponema strain 9-3143 (ATCC Accession No. ______), Treponema strain 9-3528 (ATCC Accession No. ______), Treponema strain 9-3379 (ATCC Accession No. ______), and Treponema strain 9-227 (ATCC Accession No. ______).  
     
     
         26 . The method of  claim 24 , wherein the antibody is a monoclonal antibody.  
     
     
         27 . The method of  claim 24 , wherein the antibody is immobilized on a solid surface.  
     
     
         28 . The method of  claim 24 , wherein the complex is detected using a second labeled antibody.  
     
     
         29 . The method of  claim 24 , wherein the biological sample is ungulate foot tissue.  
     
     
         30 . A method of detecting the presence of ungulate Treponema-specific nucleic acids in a biological sample, the method comprising: 
 contacting the sample with a oligonucleotide probe which specifically hybridizes with a target Treponema-specific polynucleotide sequence, thereby forming a hybridization complex; and    detecting the presence or absence of the complex.    
     
     
         31 . The method of  claim 30 , wherein the target Treponema-specific polynucleotide sequence is from Treponema strain 1-9185MED (ATCC Accession No. 202030), Treponema strain 2-1498 (ATCC Accession No. 202031), Treponema strain 7-2009 (ATCC Accession No. ______), Treponema strain 9-3301 (ATCC Accession No. ______), Treponema strain 9-3143 (ATCC Accession No. ______), Treponema strain 9-3528 (ATCC Accession No. ______), Treponema strain 9-3379 (ATCC Accession No. ______), or Treponema strain 9-227 (ATCC Accession No. ______).  
     
     
         32 . The method of  claim 30 , wherein the target Treponema-specific polynucleotide sequence is 16S rRNA.  
     
     
         33 . The method of  claim 32 , wherein the target Treponema-specific polynucleotide sequence is selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4 SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, and SEQ ID NO:8.  
     
     
         34 . The method of  claim 30 , wherein the step of detecting further comprises amplifying the target Treponema-specific polynucleotide sequence.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.